Oncology pharmacy Onco360 said on Friday that it has signed a specialty pharmacy network partnership with Celgene for its Inrebic product.
Under the specialty pharmacy network partnership, Onco360 has been selected as a specialty pharmacy provider for for Celgene's new product Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF).
MF is a serious and rare bone marrow disorder that disrupts the body's normal production of blood cells. Bone marrow is gradually replaced with fibrous scar tissue, which limits the bone marrow to make red blood cells, leading to anemia, fatigue among other symptoms.
Based on Celgene's randomized, Phase III JAKARTA trial, the Inrebic administration resulted in significantly improved MF-associated symptom burden (40% vs 9%) and significantly improved spleen response rates (37% vs 1%) compared to a placebo.
In conjunction, Inrebic is manufactured by Celgene and was approved by the US FDA on 16 August 2019.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886